The European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Trumenba®, which has been developed by Pfizer for the prevention of invasive meningococcal disease caused by serogroup B in individuals aged 10 years and older.
The acceptance marks the beginning of the regulatory review process for the vaccine in the EU, although it will be a while before it is available for sale within Europe.
Trumenba® will be the second vaccine providing protection against MenB. Bexsero®, introduced in 2013, is now routinely offered to babies under one in the UK under the NHS childhood immunisation programme.
Steve Dayman, Meningitis Now founder, said: “This is very good news. We welcome every step in vaccine development.”
“Vaccination is the only way to protect against meningitis and the more vaccines we have in our armoury the better. We look forward to the next stage in the process of making this vaccine available.”
Read more on Trumenba.
Find out more about vaccines.